Skip to main content

4 Result(s)

within J. Smyth Remove this filter Epidemiology Remove this filter

and

  1. Article

    Open Access

    Inhibition of transforming growth factor α (TGF-α)-mediated growth effects in ovarian cancer cell lines by a tyrosine kinase inhibitor ZM 252868

    The modulating effects of the epidermal growth factor (EGF) receptor-specific tyrosine kinase inhibitor ZM 252868 on cell growth and signalling have been evaluated in four ovarian carcinoma cell lines PE01, PE...

    B J B Simpson, J M S Bartlett, K G Macleod, G Rabiasz… in British Journal of Cancer (1999)

    Download PDF (414 KB)

  2. No Access

    Article

    Docetaxel (TaxotereTM) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group

    Thirty-seven eligible patients, median age 59 years (range 37-72) and median performance status 1 (0-2), with advanced, untreated, measurable gastric carcinoma were given docetaxel, 100 mg m-2 i.v. over 60 min...

    A Sulkes, J Smyth, C Sessa, LY Dirix, JB Vermorken, S Kaye… in British Journal of Cancer (1994)

  3. No Access

    Article

    Phase II trials of fosquidone, (GR63178A), in colorectal, renal and non-small cell lung cancer

    A total of 61 eligible patients with metastatic cancer have been treated in a series of Phase II trials of the novel pentacyclic pyrroloquinone, fosquidone. Tumour types were colorectal (23), renal (21), and n...

    SB Kaye, M Brampton, P Harper, J Smyth, DJ Kerr, M Gore… in British Journal of Cancer (1992)

  4. No Access

    Article

    Phase II evaluation of mitozolomide in ovarian cancer

    M Harding, D Northcott, J Smyth, NSA Stuart, JA Green… in British Journal of Cancer (1988)